Testing two immunotherapy drugs for advanced liver and bile duct cancers
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests two investigational drugs, ligufalimab and cadonilimab, for people with advanced liver cancer (hepatocellular carcinoma, HCC) or bile duct cancer (biliary tract cancer, BTC) that has not responded to previous treatment with an immunotherapy drug. The goal is to see if this combination can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer (HCC) or bile duct cancer (BTC) that cannot be removed by surgery or has spread to other parts of the body.
- Your cancer has not responded or has returned after previous treatment with an immunotherapy drug (like Keytruda or Opdivo).
- You have at least one tumor that can be measured on a CT or MRI scan.
- You are 18 years or older.
- For liver cancer, your liver function must be scored as Child-Pugh A or B7. For bile duct cancer, this does not apply.
- You must be able to do light activities (ECOG score 0-1) and have adequate blood counts and organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.
This study tests a new way of giving immunotherapy drugs for advanced liver cancer that cannot be removed by surgery. The goal is to find the best dose for each patient, which may help control the cancer with fewer side effects.
This Phase 2 trial tests a combination of lenvatinib, an immunotherapy drug (tislelizumab), and chemotherapy (gemcitabine plus cisplatin) for advanced bile duct cancer that cannot be removed with surgery. It aims to see whether this treatment can shrink tumors and improve outcomes, especially for people who have not yet had immunotherapy.
This trial tests a combination of a new immunotherapy drug (cadonilimab) with three chemotherapy drugs for advanced bile duct or gallbladder cancer that has already been treated with gemcitabine. The goal is to see if adding immunotherapy helps control the cancer better.
This trial tests a new combination of three drugs (adebrelimab, surufatinib, and liposomal irinotecan) given directly into the liver artery for advanced intrahepatic cholangiocarcinoma. The goal is to see if this approach can shrink or control the cancer.
This trial tests a new combination therapy for people with advanced bile duct or gallbladder cancer that can't be removed by surgery. It combines a drug called cadonilimab with standard chemotherapy to see if it works better than chemotherapy alone.
Hear when a new Advanced Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.